---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-002092"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:00:06.724398+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools reports preliminary FY2023 rev $106M; merger closed Jan 5, combined cash >$550M

## Summary
- Preliminary Q4 2023 revenue ~$28M and full year ~$106M for Standard BioTools.
- SomaLogic preliminary Q4 revenue ~$23M and full year ~$86M.
- Core revenue grew >10% YoY; instrument revenue grew >40% YoY.
- Merger with SomaLogic completed Jan 5, 2024; combined cash >$550M as of Dec 31, 2023.
- Company to report full Q4 and FY2023 results in early March with 2024 outlook.

## SEC filing metadata
- accession: 0001104659-24-002092
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000110465924002092/0001104659-24-002092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000110465924002092/tm2333984d4_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-002092
- JSON: https://secwatch.observer/filing/0001104659-24-002092.json
- Plain text: https://secwatch.observer/filing/0001104659-24-002092.txt

## Key facts
- Earnings Releases
  STANDARD BIOTOOLS INC. reported fourth quarter 2023 results: revenue approximately $28 million.
  - Period: fourth quarter 2023
  - Revenue: approximately $28 million
  - Result: preliminary results
  source text: Standard BioTools expects fourth quarter 2023 revenue of approximately $28 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000110465924002092/0001104659-24-002092-index.htm
- Earnings Releases
  STANDARD BIOTOOLS INC. reported full year 2023 results: revenue approximately $106 million.
  - Period: full year 2023
  - Revenue: approximately $106 million
  - Result: preliminary results
  source text: full year 2023 revenue of approximately $106 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000110465924002092/0001104659-24-002092-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.